Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

5 FDA decisions to watch in the fourth quarter of 2026

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Thursday 1 October →